Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 248

Sort by

Sort Order Select

Journal Articles

Gastrointestinal (GI) Involvement with Non-Hodgkin's Lymphoma (NHL) Impacts Outcome; A Retrospective Single Tertiary Care Center Analysis of Clinico-Pathologic Characteristics Provides an Alternate Insight to Presentation and Outcome

Ghada Zakout, FRCPATH, MRCP (UK), MBBCh (Hon), Charalampia Kyriakou

Blood (2019) 134 (Supplement_1): 5246.

https://doi.org/10.1182/blood-2019-127152

Published: 2019

Journal Articles

Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma

Samantha Brocklehurst, Neil Desai, MD MHS, Jennifer L Shah, MD, Syed Rizvi, MD, Praveen Ramakrishnan Geethakumari, MD, Kiran A Kumar, MD MBA

Blood (2019) 134 (Supplement_1): 5262.

https://doi.org/10.1182/blood-2019-131246

Published: 2019

Journal Articles

Impact of Histologic Type on Survival in Primary Parotid Lymphomas

Taha Al-Juhaishi, MD, Arushi Khurana, MBBS, Danielle Shafer, DO, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5882.

https://doi.org/10.1182/blood-2019-130981

Published: 2019

Journal Articles

Molecular Classification of Small B-Cell Lymphomas Using Digital Multiplexed Gene Expression Applicable to Formalin-Fixed Paraffin-Embedded Tissues

Min Xiao, MD PhD, Jianfeng Zhou, MD PhD, Wei Zhang, MD

Blood (2019) 134 (Supplement_1): 5770.

https://doi.org/10.1182/blood-2019-130446

Published: 2019

Journal Articles

Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab

Jonathan W. Friedberg, MD, Michael T. Brady, PhD, Myla Strawderman, MS, Brad S. Kahl, MD, John P. Leonard, MD, Izidore S. Lossos, MD, Christopher R. Flowers, MD MS, Grerk Sutamtewagul, MD, Jonathon B. Cohen, MDMS, Derick R. Peterson, PhD, Loretta J. Nastoupil, MD MSc

Blood (2019) 134 (Supplement_1): 4008.

https://doi.org/10.1182/blood-2019-127320

Published: 2019

Journal Articles

Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)

Juan Pablo Alderuccio, MD, Isildinha M Reis, PhD, Thomas M. Habermann, MD, Brian K. Link, MD, Catherine Thieblemont, MD PhD, Annarita Conconi, MD, Melissa C Larson, MS, Luciano Cascione, PhD, Wei Zhao, MD MS, James R. Cerhan, MD PhD, Emanuele Zucca, MD, Izidore S. Lossos, MD

Blood (2019) 134 (Supplement_1): 4010.

https://doi.org/10.1182/blood-2019-125008

Published: 2019

Journal Articles

Geographic Variation in the Incidence of Marginal Zone Lymphoma Subtypes and Infectious Risk Factors in the United States

Mengyang Di, MD PhD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 4012.

https://doi.org/10.1182/blood-2019-122361

Published: 2019

Journal Articles

Primary Ocular Lymphoma: A SEER Database Analysis of Patterns of Involvement and Outcomes

Arushi Khurana, MBBS, Taha Al-Juhaishi, MD, Victor Yazbeck, MD, Danielle Shafer, DO

Blood (2019) 134 (Supplement_1): 4013.

https://doi.org/10.1182/blood-2019-132011

Published: 2019

Journal Articles

Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas

Keenan T. Hartert, PhD, Kerstin Wenzl, PhD, Jordan Krull, Michelle Manske, MS, BS, Vivekananda Sarangi, Melissa C Larson, Theodora Anagnostou, MD, Ellen D. McPhail, MD, Brian K. Link, MD, Stephen M Ansell, MD PhD, James R. Cerhan, MD PhD, Dragan Jevremovic, MD PhD, Anne J Novak, PhD

Blood (2019) 134 (Supplement_1): 2764.

https://doi.org/10.1182/blood-2019-128803

Published: 2019

Journal Articles

Serum Cell-Free DNA Concentration Is Predictive of Survival Outcomes and Its Genetic Mutation Analysis May Be Viable in Obtaining Pathological Information

Yuko Shirouchi, MD, Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Hideki Uryu, MD, Takashi Okabe, MD, Norihito Inoue, MD, Takanori Fukuta, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 1498.

https://doi.org/10.1182/blood-2019-125096

Published: 2019

Journal Articles

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Martin Dreyling, MD, Panayiotis Panayiotidis, MD, George A Follows, MD PhD, Luigina Mollica, MD FRCPC, PhD, Arnon Nagler, MD MSc, Muhit Özcan, MD, Armando Santoro, Don Stevens, MD, David Trevarthen, MD, Florian Hiemeyer, MSc, Li Liu, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 1531.

https://doi.org/10.1182/blood-2019-121932

Published: 2019

Journal Articles

Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma

Victor Bobée, PharmD, Fanny Drieux, MD, Vinciane Marchand, Vincent Sater, Liana Veresezan, MD, Jean-Michel Picquenot, MD, Pierre-Julien Viailly, Marie-delphine Lanic, Mathieu Viennot, Elodie Bohers, PhD, Lucie Oberic, MD, Christiane Copie-Bergman, MD PhD, Thierry Jo Molina, MD PhD, Philippe Gaulard, MD PhD, Corinne Haioun, MD PhD, Gilles A. Salles, MD PhD, Herve Tilly, MD PhD, Fabrice Jardin, Philippe Ruminy, PhD

Blood (2019) 134 (Supplement_1): 1476.

https://doi.org/10.1182/blood-2019-122405

Published: 2019

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Loretta J. Nastoupil, MD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Felipe Samaniego, MD, Lei Feng, MS, Jiffin John, Sheryl G Forbes, Luis E. Fayad, Michael R Green, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Nathan H. Fowler, MD

Blood (2018) 132 (Supplement 1): 447.

https://doi.org/10.1182/blood-2018-99-113721

Published: 2018

Journal Articles

Genetic Landscape of Ocular Adnexa Extranodal Marginal Zone Lymphoma

Marco Magistri, PhD MS, Lanie Happ, Jeremy Ramdial, MD, Kranthi Kunkalla, Sander R Dubovy, MD, Jennifer R Chapman, MD, Francisco Vega, MD PhD, Sandeep Dave, MD, Izidore S. Lossos, MD

Blood (2018) 132 (Supplement 1): 923.

https://doi.org/10.1182/blood-2018-99-111325

Published: 2018

Journal Articles

Role of Serial Positron Emission Tomography (PET) Scans in Indolent Lymphomas' Management - Interim Results from an Ongoing Prospective Study at King Fahd Medical City, Riyadh, Saudi Arabia

Nawal Faiez Alshehry, MD, Musab Ahmed, MD, Shahid Iq bal, MD, Atta Munawar Gill, MD, Mohammad E Dawiama, MD, Ahmed Ali Butt, MD, Belal Albtoosh, BSc, RN, Ibraheem H. Motabi, MD, Mubarak S. AlGhamdi, MD, Imran Khan Tailor, MD, Syed Altaf, MD, Syed Ziauddin A. Zaidi, FRCP, FRCPath, MBBS, Shanker Raja, MD

Blood (2018) 132 (Supplement 1): 5342.

https://doi.org/10.1182/blood-2018-99-116529

Published: 2018

Journal Articles

CD19 CAR T Cell Product Exhibits High Remission Rate in Adult Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Zhitao Ying, MD PhD, Wen Wang, MD, Xiaopei Wang, MD, Wen Zheng, MD, Ningjing Lin, MD PhD, Meifeng Tu, MD PhD, Yan Xie, MD PhD, Lingyan Ping, MD PhD, Chen Zhang, MD PhD, Weiping Liu, MD PhD, Lijuan Deng, MD PhD, Ming Hao, Su Yang, Yan Zhou, BSc, James Li, Yuqin Song, MD PhD, Jun Zhu, MD PhD

Blood (2018) 132 (Supplement 1): 5388.

https://doi.org/10.1182/blood-2018-99-114527

Published: 2018

Journal Articles

HIV-Related Primary Diffuse Large B Cell Lymphoma of the Appendix. What Can We Learn?

Michelle Janania Martinez, MD, Adolfo E Diaz, MD, Cynthia Forker, MD

Blood (2018) 132 (Supplement 1): 5423.

https://doi.org/10.1182/blood-2018-99-119865

Published: 2018

Journal Articles

CXCR4 PET/CT Scan Is Superior to FDG PET/CT Scan in Accurately Defining Marginal Zone Lymphoma Nodal and Extranodal Involvement

Johannes Duell, MD, Andreas Rosenwald, Franziska Krummenast, MD, Andreas Buck, MD, Hermann Einsele, MD, Max S. Topp, Constantin Lapa, MD

Blood (2018) 132 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2018-99-118339

Published: 2018

Journal Articles

Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases

Blood (2018) 132 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2018-99-118364

Published: 2018

Journal Articles

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Marco Basset, MD, Irene Defrancesco, MD, Paolo Milani, MD, Sara Rattotti, MD, Andrea Foli, MD, Marzia Varettoni, MD, Alessandro Corso, MD, Marco Paulli, Giampaolo Merlini, MD, Luca Arcaini, MD, Giovanni Palladini, MDPhD

Blood (2018) 132 (Supplement 1): 2026.

https://doi.org/10.1182/blood-2018-99-118161

Published: 2018

NARROW

Gastrointestinal (GI) Involvement with Non-Hodgkin's Lymphoma (NHL) Impacts Outcome; A Retrospective Single Tertiary Care Center Analysis of Clinico-Pathologic Characteristics Provides an Alternate Insight to Presentation and Outcome

Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma

Impact of Histologic Type on Survival in Primary Parotid Lymphomas

Molecular Classification of Small B-Cell Lymphomas Using Digital Multiplexed Gene Expression Applicable to Formalin-Fixed Paraffin-Embedded Tissues

Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab

Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)

Geographic Variation in the Incidence of Marginal Zone Lymphoma Subtypes and Infectious Risk Factors in the United States

Primary Ocular Lymphoma: A SEER Database Analysis of Patterns of Involvement and Outcomes

Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas

Serum Cell-Free DNA Concentration Is Predictive of Survival Outcomes and Its Genetic Mutation Analysis May Be Viable in Obtaining Pathological Information

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Genetic Landscape of Ocular Adnexa Extranodal Marginal Zone Lymphoma

Role of Serial Positron Emission Tomography (PET) Scans in Indolent Lymphomas' Management - Interim Results from an Ongoing Prospective Study at King Fahd Medical City, Riyadh, Saudi Arabia

CD19 CAR T Cell Product Exhibits High Remission Rate in Adult Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

HIV-Related Primary Diffuse Large B Cell Lymphoma of the Appendix. What Can We Learn?

CXCR4 PET/CT Scan Is Superior to FDG PET/CT Scan in Accurately Defining Marginal Zone Lymphoma Nodal and Extranodal Involvement

Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only